Global Non-Specific Endonuclease Market to Reach USD 183 Billion by 2032 | CAGR 13.9% According to a newly published market research report by 24LifeSciences, global Non-Specific Endonuclease market was valued at USD 78.5 million in 2024 and is projected to reach USD 183 million by 2031, growing at a compound annual growth rate (CAGR) of 13.9% during the forecast period 2025–2031. Non-Specific Endonucleases represent a crucial class of enzymes capable of cleaving phosphodiester bonds within DNA or RNA molecules without sequence specificity. Unlike their restriction enzyme counterparts that target specific nucleotide sequences, these enzymes perform random cuts across molecular chains, making them indispensable tools for the complete degradation of nucleic acids. Their ability to process all nucleic acid forms—including single-stranded, double-stranded, linear, circular, and both natural and denatured variants—underpins their importance across numerous applications. These include vital processes in genomics research, RNA degradation protocols, sample preparation workflows, and specialized nucleic acid modification experiments where broad-spectrum cleavage is required. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/4991/non-specific-endonuclease-market

🧬📈 The Global Personalized Medicine Market is transforming healthcare! Valued at US$546.97B in 2024, it’s projected to reach nearly US$1,009.82B by 2033, growing at a 7.05% CAGR (2025–2033) 🚀 Driven by genomics, targeted therapies & precision healthcare advancements worldwide 🌍💊. Read more 👉 https://www.renub.com/personalized-medicine-market-companies-analysis-p.php #PersonalizedMedicine #PrecisionHealthcare #Genomics #TargetedTherapy #HealthcareInnovation #MarketGrowth #Biotechnology #FutureOfMedicine #GlobalHealth #RenubResearch 🧪✨